Literature DB >> 21903338

Mycobacterium paratuberculosis and autism: is this a trigger?

Coad Thomas Dow1.   

Abstract

Autism is a heterogeneous group of life-long neurologic problems that begin in childhood. Success in efforts to understand and treat autism has been mostly elusive. The role of autoimmunity in autism has gained recognition both for associated systemic autoimmune disease and the presence of brain autoantibodies in autistic children and their family members. There is an acknowledged genetic susceptibility to autism--most notably allotypes of complement C4. C4 defects are associated with several autoimmune diseases and also confer susceptibility to mycobacterial infections. Mycobacterium avium ss. paratuberculosis (MAP) causes an enteric inflammatory disease in ruminant animals (Johne's disease) and is the putative cause of the very similar Crohn's disease in humans. Humans are widely exposed to MAP in food and water. MAP has been also linked to ulcerative colitis, irritable bowel syndrome, sarcoidosis, Blau syndrome, autoimmune (Type 1) diabetes, Hashimoto's thyroiditis and multiple sclerosis. Environmental agents are thought to trigger autism in the genetically at risk. Molecular mimicry is the proposed mechanism by which MAP is thought to trigger autoantibodies. Autoantibodies to brain myelin basic protein (MBP) is a common feature of autism. This article considers the subset of autoimmunity-related autism patients and postulates that MAP, through molecular mimicry to its heat shock protein HSP65, triggers autism by stimulating antibodies that cross react with myelin basic protein (MBP).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903338     DOI: 10.1016/j.mehy.2011.08.024

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: Isn't it time to wake up?

Authors:  Georgi Tchernev; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2014-05-29

Review 2.  Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance.

Authors:  Mohtashem Samsam; Raheleh Ahangari; Saleh A Naser
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  NOD2/CARD15 gene mutation identified in a Chinese family with Blau syndrome.

Authors:  Haotian Xiang; Ting Zhang; Mengping Chen; Xiaomin Zhou; Zhen Li; Naihong Yan; Shiguang Li; Yu Han; Qiyong Gong; Xuyang Liu
Journal:  Mol Vis       Date:  2012-03-09       Impact factor: 2.367

4.  IFN-γ fails to overcome inhibition of selected macrophage activation events in response to pathogenic mycobacteria.

Authors:  Shyamala Thirunavukkarasu; Karren M Plain; Auriol C Purdie; Richard J Whittington; Kumudika de Silva
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

5.  The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients.

Authors:  Yongfei Hu; Yuqing Feng; Jiannan Wu; Fei Liu; Zhiguo Zhang; Yanan Hao; Shihao Liang; Boxing Li; Jing Li; Na Lv; Yuhui Xu; Baoli Zhu; Zhaogang Sun
Journal:  Front Cell Infect Microbiol       Date:  2019-04-03       Impact factor: 5.293

Review 6.  Neglected Facts on Mycobacterium Avium Subspecies Paratuberculosis and Type 1 Diabetes.

Authors:  Veronika Ozana; Karel Hruska; Leonardo A Sechi
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

7.  Mycobacterium avium subsp. paratuberculosis and microbiome profile of patients in a referral gastrointestinal diseases centre in the Sudan.

Authors:  Wisal A Elmagzoub; Sanaa M Idris; Maha Isameldin; Nassir Arabi; Abdelmonem Abdo; Mustafa Ibrahim; Md Anik Ashfaq Khan; Franziska Tanneberger; Sahar M Bakhiet; Julius B Okuni; Lonzy Ojok; Ahmed A Gameel; Ahmed Abd El Wahed; Michaël Bekaert; Mohamed E Mukhtar; Ahmad Amanzada; Kamal H Eltom; ElSagad Eltayeb
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.